Advertisement

LDL fractions assessed by anion-exchange high-performance liquid chromatography in patients with coronary artery disease

      LDL oxidation plays a key role in the development of atherosclerosis. Several ELISA methods had been developed to measure oxidatively modified LDL levels in blood. Plasma oxidized LDL (OxLDL) levels were measured by ELISA using monoclonal antibodies against copper OxLDL [
      • Holvoet P.
      • Mertens A.
      • Verhamme P.
      • et al.
      Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease.
      ] or oxidized phosphatidyl-choline [
      • Toshima S.
      • Hasegawa A.
      • Kurabayashi M.
      • et al.
      Circulating oxidized low density lipoprotein levels: a biochemical risk marker for coronary heart disease.
      ]. Serum malondialdehyde-modified LDL (MDA-LDL) levels were also measured by ELISA using monoclonal antibody against MDA-LDL [
      • Tanaga K.
      • Bujo H.
      • Inoue M.
      • et al.
      Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles.
      ]. Using these methods, OxLDL and MDA-LDL levels were demonstrated to be high in patients with coronary artery disease (CAD) [
      • Holvoet P.
      • Mertens A.
      • Verhamme P.
      • et al.
      Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease.
      ,
      • Toshima S.
      • Hasegawa A.
      • Kurabayashi M.
      • et al.
      Circulating oxidized low density lipoprotein levels: a biochemical risk marker for coronary heart disease.
      ,
      • Tanaga K.
      • Bujo H.
      • Inoue M.
      • et al.
      Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles.
      ]. Recently, the anion-exchange high-performance liquid chromatography (AE-HPLC) method was reported to assess OxLDL levels. By this AE-HPLC method, three LDL fractions are detected, and LDL-3, which is the most negatively charged one, is considered to reflect OxLDL [
      • Yamaguchi Y.
      • Kagota S.
      • Kunitomo M.
      • Haginaka J.
      Evidence of modified lipoprotein in the plasma of Watanabe heritable hyperlipidemic rabbits by anion-exchange high-performance liquid chromatographic assay.
      ,
      • Yamaguchi Y.
      • Haginaka J.
      • Morimoto S.
      • Fujioka Y.
      • Kunitomo M.
      Facilitated nitration and oxidation of LDL in cigarette smokers.
      ]. In 2005, Matsuoka et al. [
      • Matsuoka H.
      • Yamagishi S.
      • Umei H.
      • Kitano S.
      • Kawano K.
      • Tamoto Y.
      Novel fraction of LDL as a risk factor for metabolic syndrome.
      ] reported increased LDL-3 levels to be associated with metabolic syndrome and also to be associated with increased carotid intima-media thickness (IMT). Therefore, we expected that LDL-3 would be a biochemical marker for CAD.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Holvoet P.
        • Mertens A.
        • Verhamme P.
        • et al.
        Circulating oxidized LDL is a useful marker for identifying patients with coronary artery disease.
        Arterioscler Thromb Vasc Biol. 2001; 21: 844-848
        • Toshima S.
        • Hasegawa A.
        • Kurabayashi M.
        • et al.
        Circulating oxidized low density lipoprotein levels: a biochemical risk marker for coronary heart disease.
        Arterioscler Thromb Vasc Biol. 2000; 20: 2243-2247
        • Tanaga K.
        • Bujo H.
        • Inoue M.
        • et al.
        Increased circulating malondialdehyde-modified LDL levels in patients with coronary artery diseases and their association with peak sizes of LDL particles.
        Arterioscler Thromb Vasc Biol. 2002; 22: 662-666
        • Yamaguchi Y.
        • Kagota S.
        • Kunitomo M.
        • Haginaka J.
        Evidence of modified lipoprotein in the plasma of Watanabe heritable hyperlipidemic rabbits by anion-exchange high-performance liquid chromatographic assay.
        Atherosclerosis. 1998; 139: 323-331
        • Yamaguchi Y.
        • Haginaka J.
        • Morimoto S.
        • Fujioka Y.
        • Kunitomo M.
        Facilitated nitration and oxidation of LDL in cigarette smokers.
        Eur J Clin Invest. 2005; 35: 186-193
        • Matsuoka H.
        • Yamagishi S.
        • Umei H.
        • Kitano S.
        • Kawano K.
        • Tamoto Y.
        Novel fraction of LDL as a risk factor for metabolic syndrome.
        Circulation. 2005; 112 (Abstract): II-209
        • Ndrepepa G.
        • Braun S.
        • von Beckerath N.
        • et al.
        Oxidized low density lipoproteins, statin therapy and severity of coronary artery disease.
        Clin Chim Acta. 2005; 360: 178-186
        • Ehara S.
        • Ueda M.
        • Naruko T.
        • et al.
        Elevated levels of oxidized low-density lipoprotein show a positive relationship with the severity of acute coronary syndromes.
        Circulation. 2001; 103: 1955-1960